Protembis Gmb News Today : Breaking News, Live Updates & Top Stories | Vimarsana

NEW YORK & AACHEN, Germany, April 02, 2024--Protembis GmbH (Protembis), a privately-held emerging cardiovascular medical device company, announced today the enrollment of the first patient in the PROTEMBO Investigational Device Exemption (IDE) Pivotal Trial (NCT05873816). The trial will enroll between 250-500 randomized patients undergoing transcatheter aortic valve replacement (TAVR) in the USA and Europe with the ProtEmbo® System, an innovative next generation cerebral embolic protection devic

AACHEN, Germany, August 29, 2023--Protembis GmbH (Protembis) a privately-held emerging cardiovascular medical device company, announced today the appointment of Professor J Mocco MD, MS, FAANS, FAHA of Icahn School of Medicine at Mount Sinai, NY, USA as an independent member of their Board of Directors.

Leadership team reinforced for next phase in Protembis' clinical and regulatory growth trajectory Protembis GmbH, a privately-held emerging cardiovascular medical device company, announced today

(1) Enrollment with advanced generation device for complete cerebral protection nearing halfway mark in clinical study in Germany and Poland Protembis GmbH, a privately held emerging medical device company, announced today the successful completion of 20 clinical cases in its European regulatory study of the ProtEmbo Cerebral Protection System. The ProtEmbo System is an intra-aortic filter device that deflects embolic material away from the brain during transcatheter aortic valve replacement (TAVR). The device is a low profile system which is delivered through the left radial artery, an...